Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Subscribe To Our Newsletter & Stay Updated
